ASBMR 2022 Rare Bone Disease Highlights: Episode 3

Episode 2 September 15, 2022 00:23:01
ASBMR 2022 Rare Bone Disease Highlights: Episode 3
COR2ED Medical Education
ASBMR 2022 Rare Bone Disease Highlights: Episode 3

Sep 15 2022 | 00:23:01

/

Show Notes

In this third episode of a three-episode podcast series, COR2ED and ASBMR have partnered with patient advocates Inês Alves (European Rare Bone Forum) and Tracy Hart (Osteogenesis Imperfecta Foundation) to provide rare bone disease highlights from the ASBMR 2022 Annual Meeting, focusing on the patient perspective.

The experts opened the podcast with the importance of engaging diverse patient communities. Independent of geography, patients should be educated about their condition and prepared for clinical trial participation; advocacy groups play a central role in this engagement. The experts then discussed outcomes of the IMPACT survey in OI (osteogenesis imperfecta), whose extensive database (66 countries, >2000 participants) offers meaningful insights into the clinical, humanistic and economic challenges faced by OI patients around the world. Looking to advances in pre-clinical research, the experts reviewed data on nanoparticle-mediated delivery of small interfering RNA (siRNA) to targeted mutation sites, tested in an animal model of autosomal dominant osteopetrosis. As the experts note, patient communities struggle with lengthy research and development timelines for novel therapies; therefore, it’s important for advocates to keep communities informed about ongoing efforts.

Other Episodes

Episode 2

July 11, 2022 00:23:31
Episode Cover

Shared decision-making in nmCRPC

Shared decision-making in nmCRPC: Treatment considerations to maintain quality of life COR2ED Medical Education: Brenda Martone, a nurse practitioner at Northwestern Medicine in Chicago...

Listen

Episode 12

April 26, 2023 00:21:09
Episode Cover

Treatment sequencing in advanced mCRC patients

COR2ED Medical Education: This podcast episode discusses treatment sequencing in advanced metastatic colorectal cancer (mCRC) patients, third line and beyond.  Dr Shubham Pant from...

Listen

Episode 1

March 14, 2023 00:24:54
Episode Cover

Advanced HCC and not eligible for IO – what are the treatment options?

COR2ED Medical Education: Prof. Dr James Harding, Medical Oncologist at Memorial Sloan Kettering Cancer Center and Prof. Dr Sammy Saab, Gastroenterologist and Transplant Hepatologist...

Listen